» Articles » PMID: 36058192

The MA Demethylase FTO Promotes Renal Epithelial-mesenchymal Transition by Reducing the MA Modification of LncRNA GAS5

Overview
Journal Cytokine
Date 2022 Sep 4
PMID 36058192
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renal interstitial fibrosis (RIF) is the main pathological change of a variety of chronic kidney diseases (CKD). Epigenetic modifications of fibrosis-prone genes regulate RIF progression. This study aimed to investigate long non-coding RNA (lncRNA) N6-methyladenosine (mA) modification and its role in regulating RIF progression.

Methods: Unilateral ureteral occlusion (UUO) was employed to construct the RIF in vivo model; and TGF-β1-treated HK-2 and HKC-8 cells were used for in vitro experiments. The mRNA and protein expressions were assessed using qRT-PCR and western blot. The proliferation and migration were evaluated by EdU assay and transwell assay, respectively. In addition, levels of inflammatory cytokines were determined by ELISA assay and qRT-PCR. Moreover, lncRNA GAS5 mA level was detected using Me-RIP assay. HE and Masson staining were employed to evaluate fibrotic lesions of the kidney.

Results: FTO expression was elevated in HK-2 and HKC-8 cells after TGF-β1 treatment and mouse kidney tissue following UUO, and lncRNA GAS5 was downregulated. LncRNA GAS5 overexpression or FTO silencing suppressed TGF-β1-induced the increase of EMT-related proteins (Vimentin, Snail and N-cadherin) and inflammatory cytokines (IL-6, IL-1β and TNF-α) levels in HK-2 cells. FTO suppressed lncRNA GAS5 expression by reducing the m6A modification of lncRNA GAS5. Additionally, FTO knockdown could suppress EMT process and inflammation response induced by TGF-β1 and UUO in vitro and in vivo. As expected, FTO knockdown abrogated the promotion effects of lncRNA GAS5 silencing on TGF-β1-induced EMT process and inflammation response in HK-2 and HKC-8 cells.

Conclusion: FTO promoted EMT process and inflammation response through reducing the mA modification of lncRNA GAS5.

Citing Articles

m6A RNA modification pathway: orchestrating fibrotic mechanisms across multiple organs.

Huang X, Yu Z, Tian J, Chen T, Wei A, Mei C Brief Funct Genomics. 2025; 24.

PMID: 39756462 PMC: 11735750. DOI: 10.1093/bfgp/elae051.


METTL14 regulates inflammation in ulcerative colitis via the lncRNA DHRS4-AS1/miR-206/A3AR axis.

Wu W, Li X, Zhou Z, He H, Pang C, Ye S Cell Biol Toxicol. 2024; 40(1):95.

PMID: 39528760 PMC: 11554827. DOI: 10.1007/s10565-024-09944-8.


N6-methyladenosine (m6A) RNA modification in fibrosis and collagen-related diseases.

Tan M, Liu S, Liu L Clin Epigenetics. 2024; 16(1):127.

PMID: 39261973 PMC: 11391634. DOI: 10.1186/s13148-024-01736-5.


The role of N-methyladenosine modification in acute and chronic kidney diseases.

Qi S, Song J, Chen L, Weng H Mol Med. 2023; 29(1):166.

PMID: 38066436 PMC: 10709953. DOI: 10.1186/s10020-023-00764-w.


N6-methyladenosine methylation in kidney injury.

Wang Q, Fan X, Sheng Q, Yang M, Zhou P, Lu S Clin Epigenetics. 2023; 15(1):170.

PMID: 37865763 PMC: 10590532. DOI: 10.1186/s13148-023-01586-7.